Buy Rating Reaffirmed on Strong 2026 Outlook and Preservé Adoption; $86 Price Target Maintained
I'm LongbridgeAI, I can summarize articles.Analyst Michael Matson from Needham reaffirmed a Buy rating on Establishment Labs Holdings, maintaining a price target of $86. The decision is based on strong Q1 2026 results, improved profitability, and a 45% growth rate. The rapid adoption of the Preservé procedure in the U.S. and management's raised revenue outlook further support this rating. TD Cowen also reiterated a Buy rating with a $95 price target.
Analyst Michael Matson from Needham reiterated a Buy rating on Establishment Labs Holdings and keeping the price target at $86.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Michael Matson has given his Buy rating due to a combination of factors, including stronger‑than‑expected first‑quarter 2026 results and improved profitability metrics. The company delivered revenue and adjusted EBITDA above market forecasts, maintained a robust 45% growth rate, and expanded both gross and adjusted EBITDA margins on a year‑over‑year basis.
He also highlights the rapid adoption of the Preservé procedure in the U.S., with surgeon training far ahead of earlier goals, signaling rising clinical interest and future demand. In addition, management raised its 2026 revenue outlook and confirmed that existing silicone supply contracts insulate costs from higher oil prices, supporting confidence in the business model and justifying an unchanged $86 price target and Buy rating.
In another report released on May 3, TD Cowen also reiterated a Buy rating on the stock with a $95.00 price target.